Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
|Articles|November 12, 2014
GE Partners with Takeda to Develop Therapeutic Drugs for Liver Disease
Author(s)Pharmaceutical Technology Editors
GE Healthcare and Takeda Pharmaceutical Company announced an alliance to develop therapeutic drugs in the field of hepatic fibrosis to treat various liver diseases.
Advertisement
GE Healthcare announced on Nov. 11, 2014 an alliance agreement with Takeda Pharmaceutical to research and develop therapeutic drugs to target liver diseases. According to the alliance agreement, GE will provide Takeda with its diagnostic imaging technology to help develop diagnostic technologies and therapeutic drugs for liver diseases.
The collaboration will focus on hepatic fibrosis. The diagnosis of hepatic fibrosis is mostly conducted by a liver biopsy. With this partnership, however, Takeda will be able to use GE’s MR elastography, an MRI used to generate images depicting the elasticity of the body’s internal tissues based on pulses administered externally, to measure the relative stiffness of the liver tissue in a non-invasive manner.
Source:
Advertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5